Source
Centre Hospitalier Universitaire de Cocody (Abidjan), Service de Pharmacologie Clinique, Abidjan, Côte d'Ivoire. ebalayssac@yahoo.fr
Abstract
OBJECTIVE:
To precise adverse effects of atazanavir, fosamprenavir and tipranavir "in real life".
METHOD:
Descriptive study of 3 protease inhibitor adverse effects stored in the French Bank of Pharmacovigilance.
RESULTS:
Nineteen adverse effects having at least possible links with antiretroviral drugs studied were reported. It was essentially hepatobiliary (atazanavir: 29/59, tipranavir: 4/6) and skin (fosamprenavir: 10/20) adverse reactions. These reactions, relatively "serious" (35.1%) led to the interruption of the person (or persons) medication (s) suspected (s) in 69 folds (82.1%) and evolved to healing without sequelae in 68 folds (81%).
CONCLUSION:
The drug side effects were for the most expected. However, their frequency and their seriously underline the interest of a post-AMM monitoring to reassess the drugs risk-benefit report.
2010 Société Française de Pharmacologie et de Thérapeutique.